nference

Shedding light on Long-COVID risk factors has been a personal quest for me. Delighted to share the latest AI study with over 1000 long-COVID patients published in Cell Press iScience with my colleagues from nference, Mayo Clinic, Vir Biotechnology, Inc. and MaineHealth Maine Medical Center. Our study reveals that a perturbed metabolic signature during the acute COVID infection phase (initial few days of SARS-COV-2 infection) including higher triglycerides, low levels of “good cholesterol” (low HDL) and high neutrophil-to-lymphocyte NLR ratio (a prognostic marker used in cardiovascular mortality risk stratification) are correlated with increased long-COVID risk. This is further correlated with more severe acute infection phases in patients who go on to receive a formal long COVID diagnosis weeks or even months after the initial COVID-19 index infection. Such a clinical “early marker” for future long COVID onset can be a useful clinical diagnostic tool for prognostic monitoring of patients. Such a clinical decision support system can provide critical insights to improve the Quality of Life for patients battling the debilitating sustained symptoms like brain fog, chronic fatigue syndrome and postural tachycardia. This cluster of life-altering symptoms has had such profound negative impact on tens of thousands of patients in just the USA alone, with the global magnitude of long-COVID anticipated to be far larger than can be measured today. First of many studies to come surely, but has profound implications for how AI can be built from longitudinal patient de-identified data over the powerful Mayo Clinic Platform and more saliently, how the AI diagnostic algorithms developed and validated thus can be deployed to save countless other patient lives globally over the years to come. Congratulations to the terrific team of AI engineers, physicians, scientists, and nurse practitioners who collaborated intensely to make this study possible (Pritha Ghosh Michiel JM Niesen Colin Pawlowski Hari Bandi Unice Yoo Patrick Lenehan Praveen Kumar M Mihika Nadig Sankar Ardhanari John O'Horo AJ Venkatakrishnan Cliff Rosen Amalio Telenti Ryan T. Hurt, MD, PhD ) https://lnkd.in/eqcK5iRY. #MayoClinic #AI #nference #Covid19 #longcovid #pandemic #mentalhealth

nference is proud to announce a strategic research alliance with Takeda, aimed at advancing precision medicine in the treatment of Inflammatory Bowel Disease (#IBD). Introducing Project #SUCCINCT (Systematic UC & Crohn’s INformatics Clinical Toolkit), an innovative initiative leveraging our advanced artificial intelligence (#AI) capabilities to analyze de-identified electronic health records. This collaboration seeks to identify personalized treatment approaches, thereby improving patient care for those affected by IBD. IBD, which includes Crohn’s disease and ulcerative colitis, is a chronic and debilitating condition affecting millions globally. The complexity and variability of IBD pose significant challenges in managing and treating the disease. Identifying effective treatments is crucial for improving the quality of life for patients, reducing healthcare costs, and minimizing the long-term complications associated with the disease. Project SUCCINCT aims to address these challenges by providing more targeted and effective therapeutic options through AI-driven insights. "This initiative will leverage our state-of-the-art AI-enabled platform to unlock previously undiscovered insights and information that will help facilitate more precise and targeted interventions with the disease.” - Maulik Nanavaty, President of Ventures at nference and CEO at Anumana. We are excited about the potential of this collaboration to transform the landscape of IBD treatment and look forward to the advancements it will bring. #PrecisionMedicine #RealWorldEvidence #IBD #nference #Takeda Learn more: https://lnkd.in/eWFzPYPc

Excited to share that Takeda is advancing an AI collaboration with nference in the Gasteroenterology space. Project SUCCINCT (Systematic UC & Crohn’s INformatics Clinical Toolkit) will leverage multimodal AI to identify Inflammatory Bowel Disease (IBD) patients who could benefit from Takeda's advanced medical interventions, resulting in personalized treatment options and improved clinical care outcomes. Congratulations to the teams involved in this important initiative to make AI diagnostics & interventions work for IBD patients worldwide! https://lnkd.in/e3BiRA24 Vijay Yajnik: “AI-driven innovation represents a promising new frontier in medicine. We’re pleased to join forces with nference on this vital research endeavor seeking to improve the diagnostic and treatment journey for patients around the world living with IBD,” said Vijay Yajnik, MD, PhD, Vice President, Head of U.S. Medical in Gastroenterology at Takeda, a biopharmaceutical leader headquartered in Japan with a global hub in Cambridge, Mass. “By harnessing AI, we can push beyond the boundaries of what is possible today to empower healthcare providers with information to help tailor treatment selection for patients, precisely when needed.” #AI #ArtificialIntelligence #Takeda #nference #GI #gut #IBD #crohns #ulcerativecolitis #precisionmedicine #personalizedmedicine

I am excited to share a new invited commentary in the North Carolina Medical Journal, co-authored by Dean Mary E. Klotman M.D., and myself. Our piece outlines the critical role that academic medical centers, like Duke University School of Medicine, are poised to play as #healthAI is integrated into multiple facets of patient care, healthcare system operations, and medical education. You can read more about our insights here: https://lnkd.in/eGUCZ8gg

We are honored that Mayo Clinic is once again recognized on U.S. News & World Report's Best Hospitals 2024-2025 Honor Roll, with Mayo Clinic in Rochester continuing to be the hospital with the most specialties ranked first in the nation. Thank you to our Category-of-One staff for always putting the needs of our patients first, inspiring others through hope and healing, and making it possible to lead in transforming the future of healthcare. https://lnkd.in/gNFgqRMx

We have a new look… with the same inception pledge to make the Worlds biomedical knowledge computable and actionable for patients globally. https://nference.com/

nference continues to lead the way for #AI innovation in healthcare: 3 years ago, nference published the first-in-class peer-reviewed study demonstrating that the unstructured EHR clinical notes can be fully de-identified in a HIPAA-compliant way using AI automation: Cell Press https://lnkd.in/e3AVdPGh Now, the AI team from nference has co-authored another best-in-class AI study with outstanding physician leaders from the Mayo Clinic, Duke University Health System and Vanderbilt University Medical Center. The team's preprint published ahead of peer-review demonstrates how our AI automation has been scaled-up and pressure tested for HIPAA-compliant de-identification of unstructured EHR information (a breakthrough innovation in this "Age of Generative AI"). Protecting patient privacy is a core tenet of how nference and our top-ranked AMC partners including Mayo Clinic Platform, Emory Healthcare, Banner Health, Vanderbilt University, and Duke University are making the world's biomedical knowledge secure and actionable for benefiting patients worldwide. Hearty congratulations to the co-authors of this new study -- Karthik Murugadoss, Saivikas Killamsetty, Deeksha Doddahonnaiah, Nakul Iyer, Michael Pencina, Jeffrey Ferranti, MD, MS, John Halamka, M.D., M.S., Brad Malin, Sankar Ardhanari https://lnkd.in/e8TjKZqJ

Delighted to share the publication of the first-in-class AI tech to detect silent-yet-deadly Pulmonary Hypertension from a routine ECG (EKG) test. Hearty congratulations to the authors from nference, Anumana, Mayo Clinic, Vanderbilt University Medical Center and Johnson & Johnson who have worked tirelessly for several years to bring this ECG AI innovation to patients ("the internet of the human body"). Teaching AI to speak the language of the heart (ECG) -- as early digital diagnostics for deadly pathologies where actionable interventions exist in the market -- will save millions of patients lives year on year. Tremendously proud of the incredible team making this dream a reality for patients worldwide: Peer-reviewed publication in European Respiratory Journal (ESR) - https://lnkd.in/gnsh8JmP Press Release - https://lnkd.in/eWYxCDFg Anumana - www.anumana.ai nference - www.nference.com Hilary Dubrock, Tyler Wagner, Ph.D, Katherine Carlson, Corinne Carpenter, Samir Awasthi, Zachi Attia, Robert Frantz, Paul Friedman, Suraj Kapa, Jeffrey Annis, Evan Brittain, anna hemnes, Sam Asirvatham, Mona Selej M.D.,M.S. Peter Agron, PhD, Peter Agron, Emily Kogan, Debbie Quinn, Preston Dunnmon, Najat Khan, PhD

Our latest #clinicalstudy, conducted in collaboration with Mayo Clinic, #Vanderbilt University Medical Center (VUMC), and Johnson & Johnson Innovative Medicine, reveals exciting results! In the study An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension published in European Respiratory Journal, we showed that an investigational AI algorithm has the potential to detect #pulmonaryhypertension #PH using routine 12-lead ECG data. “The promising data from our study suggests that an AI algorithm has the potential to non-invasively detect PH at an early stage using standard ECGs,” said Dr. Hilary Dubrock , Mayo Clinic pulmonologist and lead author of the study. “This marks a significant step forward in care and management of PH patients who often have a long diagnostic journey.” Read the full study here: https://lnkd.in/eE8SUMP6 Read the press release here: https://lnkd.in/eHAh4MxF Congratulations to all the authors of the study! Tyler Wagner, Ph.D, Katherine Carlson, Samir Awasthi, Zachi Attia, Robert Frantz, Paul Friedman, Suraj Kapa, Jeffrey Annis, Evan Brittain, anna hemnes, Samuel J. Asirvatham, Melwin Babu, Ashim Prasad, Unice Yoo, Rakesh Barve, Ph.D, Mona Selej M.D.,M.S., Peter Argon, Emily Kogan, Deborah Quinn, Preston Dunnmon, Najat Khan, PhD, Venky Soundararajan

Delighted to share the publication of the first-in-class AI tech to detect silent-yet-deadly Pulmonary Hypertension from a routine ECG (EKG) test. Hearty congratulations to the authors from nference, Anumana, Mayo Clinic, Vanderbilt University Medical Center and Johnson & Johnson who have worked tirelessly for several years to bring this ECG AI innovation to patients ("the internet of the human body"). Teaching AI to speak the language of the heart (ECG) -- as early digital diagnostics for deadly pathologies where actionable interventions exist in the market -- will save millions of patients lives year on year. Tremendously proud of the incredible team making this dream a reality for patients worldwide: Peer-reviewed publication in European Respiratory Journal (ESR) - https://lnkd.in/gnsh8JmP Press Release - https://lnkd.in/eWYxCDFg Anumana - www.anumana.ai nference - www.nference.com Hilary Dubrock, Tyler Wagner, Ph.D, Katherine Carlson, Corinne Carpenter, Samir Awasthi, Zachi Attia, Robert Frantz, Paul Friedman, Suraj Kapa, Jeffrey Annis, Evan Brittain, anna hemnes, Sam Asirvatham, Mona Selej M.D.,M.S. Peter Agron, PhD, Peter Agron, Emily Kogan, Debbie Quinn, Preston Dunnmon, Najat Khan, PhD